<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab

    Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.

    Biodesix Announces Publication of Seminal PROSE Study in THE LANCET ONCOLOGY

    Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)

    AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC

    AVEO and Biodesix announce a groundbreaking partnership on ficlatuzumab

    Biodesix Receives Highmark Blue Cross Blue Shield Coverage for VeriStrat Test

    Biodesix' Veristrat test is now covered by Highmark BCBS.

    Biodesix to Present at World CDx

    Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.

    Biodesix Receives CE Mark for VeriStrat Specimen Collection and Shipping Kit

    CE Mark clears Biodesix to make VeriStrat results available to physicians in the European Union and other countries recognizing the CE Mark.

    Biodesix Closes Series E Financing

    Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.

    Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

    VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).

    Biodesix and Capital Royalty Close Financing Transaction

    Biodesix has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.

    Biodesix Adds to Series E Financing

    Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.